Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS +1.45%29 EV-to-Revenue is 820.10 as of Sep. 13, 2026, which is 92% above its 10-year median of 426.74. GuruFocus rates XSWX:XLS with a GF Score™ of 29/100 and a GF Value™ of CHF6.94 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 963 Biotechnology companies, Xlife Sciences AG ranks worse than 94.39% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xlife Sciences AG's enterprise value is CHF225.53 Mil.
Xlife Sciences AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.28 Mil. Therefore, Xlife Sciences AG's EV-to-Revenue for today is 820.10.
The historical rank and industry rank for Xlife Sciences AG's EV-to-Revenue or its related term are showing as below:
XSWX:XLS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 330.26 Med: 426.74 Max: 1212.62
Current: 820.1
During the past 8 years, the highest EV-to-Revenue of Xlife Sciences AG was 1212.62. The lowest was 330.26. And the median was 426.74.
XSWX:XLS's EV-to-Revenue is ranked worse than 94.39% of 963
companies
in the Biotechnology industry
Industry Median: 8.49
vs XSWX:XLS: 820.10
As of today (2026-09-13), Xlife Sciences AG's stock price is CHF14.00.
Xlife Sciences AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.04. Therefore, Xlife Sciences AG's PS Ratio for today is 378.38.
Xlife Sciences AG's share price for today is CHF14.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG EV-to-Revenue Related Terms
Xlife Sciences AG EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, MRNA: EV-to-Revenue Comparison
For the Biotechnology subindustry, Xlife Sciences AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG EV-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's EV-to-Revenue falls into.
Xlife Sciences AG's current Enterprise Value is CHF225.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a EV-to-Revenue of 820.10 as of Sep. 13, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Xlife Sciences AG and its competitors. This is 92% above median its historical median of 426.74. Over the past decade, Xlife Sciences AG's EV-to-Revenue has ranged from 330.26 to 1,212.62. According to the industry distribution chart, Xlife Sciences AG ranks #909 out of 963 companies in the Biotechnology industry, placing it in the top 94.4%.
Is Xlife Sciences AG's EV-to-Revenue too high?
Xlife Sciences AG's current EV-to-Revenue of 820.10 is 92% above median its 10-year median of 426.74. Over the past 10 years, this metric has ranged from a low of 330.26 to a high of 1,212.62. The Biotechnology industry median EV-to-Revenue is 8.49. Xlife Sciences AG's value of 820.10 is 9559.6% above this industry median. Based on the distribution chart, Xlife Sciences AG ranks #909 out of 963 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EV-to-Revenue compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #909 out of 963 companies for EV-to-Revenue. This places Xlife Sciences AG in the lower half of its industry. The industry median EV-to-Revenue is 8.49. Xlife Sciences AG's value of 820.10 is 9559.6% above this benchmark. Historically, Xlife Sciences AG's own EV-to-Revenue has ranged from 330.26 to 1,212.62 over the past decade. While the company's 10-year median is 426.74 vs. the industry median of 8.49, Xlife Sciences AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 8.49, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current EV-to-Revenue of 820.10 is 9559.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 8.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current EV-to-Revenue is 820.10, which is 92% above median its own 10-year median of 426.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF6.94, compared to a current price of CHF14.00 — trading 101.7% above its estimated fair value. The current EV-to-Revenue is 820.10, which is 92% above median its 10-year median of 426.74 and 9559.6% above the Biotechnology industry median of 8.49. Xlife Sciences AG's overall GF Score™ is 29/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current EV-to-Revenue is 820.10 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF14.00 is trading 101.7% above its estimated GF Value™ of CHF6.94.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
EV-to-Revenue: 820.10 (92% above median its 10-year median of 426.74)
GF Value™: CHF6.94 vs. price of CHF14.00 (101.7% above fair value)
Industry Position: 9559.6% above the Biotechnology median (#909 of 963)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
29GF Score
Get the complete analysis for XSWX:XLS
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
